Augmentation of therapy for combined loss of heterozygosity 1p and 16q in favorable histology wilms tumor: A Children's Oncology Group AREN0532 and AREN0533 study report

behalf of the AREN0532 and AREN0533 study committees.

Research output: Contribution to journalArticlepeer-review

37 Scopus citations

Fingerprint

Dive into the research topics of 'Augmentation of therapy for combined loss of heterozygosity 1p and 16q in favorable histology wilms tumor: A Children's Oncology Group AREN0532 and AREN0533 study report'. Together they form a unique fingerprint.

Medicine & Life Sciences